Peters AL, et al. - In this post hoc analysis of an 18-week randomized trial, researchers investigated the usefulness of calculating baseline glycated hemoglobin (HbA1c), postprandial glucose (PPG) increments and nocturnal glucose change in predicting effectiveness and safety results in response to bolus insulin intensification in people with type 2 diabetes (T2D). They assessed 236 metformin-treated participants with T2D: 116 received fast-acting insulin aspart (faster aspart) basal-bolus therapy and 120 received basal-only insulin. For baseline HbA1c, significantly greater treatment differences were recorded for change in end-of-trial PPG increments, but not end-of-trial HbA1c. According to findings, both nocturnal glucose and PPG increments might be more useful than HbA1c in identifying T2D subgroups that would benefit most from bolus intensification.